New research indicates that individuals using GLP-1 medications like Ozempic and Wegovy may lose weight without essential nutritional support, threatening long-term health.
Researchers from UCL and the University of Cambridge found that people on these prescription weight-loss drugs often lack necessary dietary guidance. Without it, they face risks of nutrient deficiencies and muscle loss.
Key Findings from the Obesity Reviews Study
A study published in Obesity Reviews, led by Dr. Marie Spreckley from the University of Cambridge, identified limited high-quality evidence on nutritional advice delivery with these drugs. Major gaps exist in understanding how dietary support affects calorie intake, body composition, protein intake, and patient experiences.
Semaglutide and tirzepatide, branded as Ozempic, Wegovy, and Mounjaro, mimic glucagon-like peptide-1 (GLP-1), a hormone released after eating. They reduce appetite, boost fullness, and curb cravings, cutting daily calorie intake by 16-39%.
However, little research examines impacts on diet quality, protein, or micronutrients. Evidence suggests lean body mass, including muscle, can comprise up to 40% of total weight lost.
Risks of Inadequate Nutritional Support
Dr. Adrian Brown, NIHR Advanced Fellow at UCL's Centre of Obesity Research and study corresponding author, stated:
"Obesity management medications work by suppressing appetite, increasing feelings of fullness, and altering eating behaviors, which often leads people to eat significantly less. This can be highly beneficial for individuals living with obesity, as it supports substantial weight loss and improves health outcomes.
However, without appropriate nutritional guidance and support from healthcare professionals, there is a real risk that reduced food intake could compromise dietary quality, meaning people may not get enough protein, fibre, vitamins, and minerals essential for maintaining overall health."
Access to Treatment and Care Gaps
NICE guidance recommends semaglutide for weight management in adults with BMI ≥35 kg/m² and comorbidities like type 2 diabetes or cardiovascular disease. It requires integration with reduced-calorie diets and physical activity.
Yet, most UK users—around 1.5 million, 95% via private providers—lack consistent nutritional advice.
Dr. Marie Spreckley from the MRC Epidemiology Unit at Cambridge noted:
"Use of GLP-1 receptor agonist therapies has increased rapidly in a very short period of time, but the nutritional support available to people using these medications has not kept pace. Many people receive little or no structured guidance on diet quality, protein intake, or micronutrient adequacy while experiencing marked appetite suppression.
If nutritional care is not integrated alongside treatment, there's a risk of replacing one set of health problems with another, through preventable nutritional deficiencies and largely avoidable loss of muscle mass. This represents a missed opportunity to support long-term health alongside weight loss."
Poor micronutrient intake raises risks of fatigue, weakened immunity, hair loss, and osteoporosis. Muscle loss increases weakness, injury, and fall risks.
Limited Evidence and Bariatric Surgery Lessons
Only 12 studies addressed nutrition with semaglutide or tirzepatide, varying widely without standardized protocols.
Researchers recommend drawing from bariatric surgery protocols, which yield similar outcomes.
Dr. Cara Ruggiero, co-author from Cambridge's MRC Epidemiology Unit, said:
"While GLP-1 receptor agonists are increasingly used, there remains a clear gap in structured nutritional guidance. In the interim, we can draw on well-established post-bariatric nutrition principles. Our previous work highlights the importance of prioritizing nutrient-dense foods including high-quality protein intake, ideally distributed evenly across meals, to help preserve lean mass during periods of reduced appetite and rapid weight loss."
Diet Quality, Fat Intake, and Eating Patterns
- Insufficient evidence supports strict low-fat diets, but some studies show high total and saturated fat intake.
- Individualized fat guidance aligning with national recommendations may help.
- Small, frequent meals could reduce nausea and improve tolerability early in treatment.
The team calls for patient input via AMPLIFY to shape real-world support.
Dr. Spreckley, leading AMPLIFY, added:
"These medications are transforming obesity care, but we know very little about how they shape people's daily lives, including changes in appetite, eating patterns, wellbeing, and quality of life. That's what we'll explore, working in particular with people from communities historically under-represented in obesity research, to help shape the future of obesity treatment."
Reference: "Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence" by Marie Spreckley, Cara F. Ruggiero, and Adrian Brown, 7 January 2026, Obesity Reviews. DOI: 10.1111/obr.70079.
